BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases 2022; 10(14): 4327-4333 [PMID: 35663066 DOI: 10.12998/wjcc.v10.i14.4327]
URL: https://www.wjgnet.com/2307-8960/full/v10/i14/4327.htm
Number Citing Articles
1
Nicola Humphry. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to AcceptanceEMJ Gastroenterology 2022; : 2 doi: 10.33590/emjgastroenterol/10106137
2
Celia Gómez-Labrador, Elena Ricart, Marisa Iborra, Eva Iglesias, María Dolores Martín-Arranz, Luisa de Castro, Ruth De Francisco, Francisco Javier García-Alonso, Ana Sanahuja, Carla J. Gargallo-Puyuelo, Francisco Mesonero, María José Casanova, Míriam Mañosa, Montserrat Rivero, Marta Calvo, Mónica Sierra-Ausin, Carlos González-Muñoza, Xavier Calvet, Santiago García-López, Jordi Guardiola, Lara Arias García, Lucía Márquez-Mosquera, Ana Gutiérrez, Yamile Zabana, Mercè Navarro-Llavat, Rufo Lorente Poyatos, Marta Piqueras, Leyanira Torrealba, Fernando Bermejo, Ángel Ponferrada-Díaz, José L. Pérez-Calle, Manuel Barreiro-de Acosta, Coral Tejido, José Luis Cabriada, Ignacio Marín-Jiménez, Óscar Roncero, Yolanda Ber, Luis Fernández-Salazar, Blau Camps Aler, Alfredo J. Lucendo, Jordina Llaó, Luis Bujanda, Carmen Muñoz Villafranca, Eugeni Domènech, María Chaparro, Javier P. Gisbert. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDAPharmaceutics 2024; 16(5): 629 doi: 10.3390/pharmaceutics16050629
3
Shannon White, Ryan Morrow, Ingrid Pan, Edwin F. de Zoeten. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric GastroenterologistsJournal of Pediatric Gastroenterology & Nutrition 2023; 76(6): 701 doi: 10.1097/MPG.0000000000003757